MARIE RENOIT: Open Payments
NPI 1932209814 · MIAMI, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,016 in 75 payments from 15 companies in 2025. Trend: 2023 $1,000 · 2024 $1,457 · 2025 $2,016
Food & beverage: $2,016
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 16 | $386 |
| SCPHARMACEUTICALS INC. | 6 | $262 |
| Actelion Pharmaceuticals US, Inc. | 7 | $233 |
| Merck Sharp & Dohme LLC | 8 | $194 |
| Alnylam Pharmaceuticals Inc. | 4 | $191 |
| PFIZER INC. | 7 | $140 |
| Bayer Healthcare Pharmaceuticals Inc. | 6 | $133 |
| Novo Nordisk Inc | 5 | $100 |
| E.R. Squibb & Sons, L.L.C. | 4 | $94 |
| United Therapeutics Corporation | 3 | $78 |
Products named: FUROSCIX, UPTRAVI, WAINUA, AMVUTTRA, WINREVAIR, VYNDAQEL, FARXIGA, Kerendia.
Industry payments across FL — which companies pay providers there.
